CD49f+ Cell Isolation for Pluripotent Stem Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies face challenges in using human pluripotent stem cells due to ethical issues, tumorigenicity, and immune rejection, and there is a need for a source of human pluripotent stem cells derived from adult tissue that is safe, efficient, and feasible for clinical use, as well as a protocol for their in vitro culture for treating tissue damages and chronic diseases.
Innovation Solution
A method involving the isolation and enrichment of CD49f+ cells from adult human tissue, specifically through centrifugation and characterization, followed by culturing these cells in a medium conditioned with primary hepatocytes or hepatic cell lines to promote expansion and differentiation, resulting in a population of pluripotent stem cells that are non-tumorigenic and capable of differentiating into all three germ layers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If embryonic stem cells are used for therapy, then pluripotency and self-renewal capacity are achieved, but ethical issues, tumorigenicity, and immune rejection occur
Solution Approach 1:
The invention segments the stem cell field into distinct categories: embryonic stem cells (with their known problems), induced pluripotent stem cells (iPSCs), and a newly identified population of pluripotent stem cells from adult human tissue. This segmentation allows selection of the most appropriate cell source for therapy, avoiding the harmful factors associated with ESCs while maintaining pluripotency.
Solution Approach 2:
The invention introduces an intermediary cell population - pluripotent stem cells isolated from adult human tissue - that serves as a bridge between the limitations of ESCs and the differentiation potential of somatic cells. These intermediate cells provide pluripotency without the ethical and tumorigenicity concerns of ESCs, and without the low derivation frequency of iPSCs.
2Object-affected harmful factors
If induced pluripotent stem cells are used to avoid ethical issues and immune rejection, then patient-matched cells are obtained, but tumorigenicity remains and derivation frequency is low
Solution Approach 1:
The invention copies the successful approach of iPSCs (using adult tissue to avoid ethical issues and immune rejection) but creates a distinct cell population that is isolated directly from adult tissue rather than reprogrammed. This copying approach maintains the advantages of patient-matched cells while avoiding the tumorigenicity and low derivation frequency associated with iPSC reprogramming.
3Productivity
If mouse embryonic stem cells are used as model organisms, then research into human biology is advanced, but fundamental differences in molecular signatures, signaling pathways, colony shape, growth rate, surface markers, and developmental potential exist between mouse and human ESCs
Solution Approach 1:
The invention enables human biology research to serve itself by providing a human-derived cell model (pluripotent stem cells from adult human tissue) that inherently possesses human molecular signatures, signaling pathways, and developmental potential. This eliminates the need to rely on mouse models and subsequently translate findings to humans, allowing research to be conducted directly in the human system from the outset.
4Ease of manufacture
If a protocol for culturing human pluripotent stem cells from adult tissue is established, then practical cell-based therapy becomes feasible, but challenges in in vitro expansion and differentiation efficiency remain
Solution Approach 1:
The invention establishes a culture protocol that optimizes specific parameters (medium composition, coating substrates, growth factors) to enable efficient in vitro expansion and differentiation of pluripotent stem cells from adult human tissue. By systematically adjusting these cultural parameters, the protocol achieves both practical feasibility and high productivity for therapeutic applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a practical means for cell-based therapy by isolating and expanding human pluripotent stem cells from adult tissue, overcoming ethical and safety concerns, and enabling their use in treating tissue damages and chronic diseases through effective differentiation and expansion protocols.
Implementation Method 1
centrifuging the sample at 3,000×g-15,000×g and obtaining a pellet
Data Source
AI summary
Certain populations of small cells present in adult human tissue can undergo activation/development to form human pluripotent stem cell populations. These small cells are generally less than six micrometers in diameter and are CD49f-positive, and are referred to herein as human early stage precursors or CD49f+ cells. Accordingly, provided are cell populations and compositions with enriched CD49f+ cells from adult human tissue samples and methods and compositions for promoting activation/development of these CD49f+ cells. Upon differentiation, the activated stem cells can be used for various therapeutic purposes.